Connect Biopharma Australia Pty Ltd

Quick facts

Marketed products

• Moxifloxacin (Avelox) · Infectious Disease
  Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.

Phase 1 pipeline

• CBP-174
• CBP-307

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Connect Biopharma Australia Pty Ltd portfolio CI brief
• Connect Biopharma Australia Pty Ltd pipeline updates RSS